NASDAQ:NVUS - Novus Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$4.45 -0.30 (-6.32 %)
(As of 02/22/2019 04:00 PM ET)
Previous Close$4.75
Today's Range$4.40 - $4.81
52-Week Range$1.52 - $8.61
Volume26,583 shs
Average Volume30,544 shs
Market Capitalization$41.93 million
P/E Ratio-1.93
Dividend YieldN/A
Beta3.55
Novus Therapeutics, Inc., a pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is (OP-02), a surfactant-based combination drug product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology (OP-01) that could be used to deliver drugs into the ear, nose, and sinus cavities. Novus Therapeutics, Inc. is headquartered in Irvine, California.

Receive NVUS News and Ratings via Email

Sign-up to receive the latest news and ratings for NVUS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NVUS
CUSIPN/A
Phone949-238-8090

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.75 per share

Profitability

Net Income$-13,110,000.00

Miscellaneous

Employees7
Market Cap$41.93 million
Next Earnings Date4/1/2019 (Estimated)
OptionableNot Optionable

Novus Therapeutics (NASDAQ:NVUS) Frequently Asked Questions

What is Novus Therapeutics' stock symbol?

Novus Therapeutics trades on the NASDAQ under the ticker symbol "NVUS."

How were Novus Therapeutics' earnings last quarter?

Novus Therapeutics Inc (NASDAQ:NVUS) posted its quarterly earnings data on Tuesday, November, 13th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, beating analysts' consensus estimates of ($0.38) by $0.01. View Novus Therapeutics' Earnings History.

When is Novus Therapeutics' next earnings date?

Novus Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, April 1st 2019. View Earnings Estimates for Novus Therapeutics.

What price target have analysts set for NVUS?

1 brokerages have issued twelve-month price targets for Novus Therapeutics' shares. Their forecasts range from $12.00 to $12.00. On average, they expect Novus Therapeutics' share price to reach $12.00 in the next year. This suggests a possible upside of 169.7% from the stock's current price. View Analyst Price Targets for Novus Therapeutics.

What is the consensus analysts' recommendation for Novus Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novus Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Novus Therapeutics.

Has Novus Therapeutics been receiving favorable news coverage?

Headlines about NVUS stock have trended somewhat positive on Saturday, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Novus Therapeutics earned a news impact score of 1.7 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the immediate future.

Who are some of Novus Therapeutics' key competitors?

What other stocks do shareholders of Novus Therapeutics own?

Who are Novus Therapeutics' key executives?

Novus Therapeutics' management team includes the folowing people:
  • Mr. Gregory J. Flesher, CEO & Director (Age 49)
  • Dr. Catherine C. Turkel, Pres (Age 58)
  • Mr. Jon Kuwahara CPA, Sr. VP of Fin. & Admin. (Age 54)

Who are Novus Therapeutics' major shareholders?

Novus Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include National Asset Management Inc. (1.28%). Company insiders that own Novus Therapeutics stock include Catherine C Turkel and Gregory J Flesher. View Institutional Ownership Trends for Novus Therapeutics.

Which institutional investors are buying Novus Therapeutics stock?

NVUS stock was acquired by a variety of institutional investors in the last quarter, including National Asset Management Inc.. Company insiders that have bought Novus Therapeutics stock in the last two years include Catherine C Turkel and Gregory J Flesher. View Insider Buying and Selling for Novus Therapeutics.

How do I buy shares of Novus Therapeutics?

Shares of NVUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Novus Therapeutics' stock price today?

One share of NVUS stock can currently be purchased for approximately $4.45.

How big of a company is Novus Therapeutics?

Novus Therapeutics has a market capitalization of $41.93 million. The biopharmaceutical company earns $-13,110,000.00 in net income (profit) each year or ($2.30) on an earnings per share basis. Novus Therapeutics employs 7 workers across the globe.

What is Novus Therapeutics' official website?

The official website for Novus Therapeutics is http://www.northviewreit.com.

How can I contact Novus Therapeutics?

Novus Therapeutics' mailing address is 19900 MACARTHUR BLVD. SUITE 550, IRVINE CA, 92612. The biopharmaceutical company can be reached via phone at 949-238-8090 or via email at [email protected]


MarketBeat Community Rating for Novus Therapeutics (NASDAQ NVUS)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  171 (Vote Outperform)
Underperform Votes:  162 (Vote Underperform)
Total Votes:  333
MarketBeat's community ratings are surveys of what our community members think about Novus Therapeutics and other stocks. Vote "Outperform" if you believe NVUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel